Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CA-125

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    159 result(s) found for: CA-125. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2008-000245-55 Sponsor Protocol Number: AGO-GYN 7 Start Date*: 2008-06-24
    Sponsor Name:GYN Research GmbH
    Full Title: Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
    Medical condition: Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004913-14 Sponsor Protocol Number: CEPO906A2203 Start Date*: 2005-08-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label Phase I/II dose escalation study evaluating the safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer
    Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include y...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004099-71 Sponsor Protocol Number: MITO29 Start Date*: 2018-03-27
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Randomized Phase II study on Decitabine plus Carboplatin versus physician’s choice chemotherapy in recurrent, platinum-resistant ovarian cancer
    Medical condition: Platinum-resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006888 Ca ovary LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004952-14 Sponsor Protocol Number: 0209-01 Start Date*: 2021-07-07
    Sponsor Name:Constellation Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Tumors
    Medical condition: advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, ovarian clear cell cancer, endometrial carcinoma, GCB-DLBCL, small cell lu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2017-004690-14 Sponsor Protocol Number: NA Start Date*: 2021-01-12
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026311 Malignant neoplasm of ovary and other uterine adnexa LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061535 Ovarian neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005458-27 Sponsor Protocol Number: MK-4830-002 Start Date*: 2022-04-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
    Medical condition: First-line treatment of advanced High Grade Serous Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003789-24 Sponsor Protocol Number: SHH4489g Start Date*: 2008-12-24
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN A SECOND OR THIR...
    Medical condition: OVARIAN CANCER (SECOND OR THIRD COMPLETE REMISSION)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005392-39 Sponsor Protocol Number: 213357 Start Date*: 2022-02-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL). C...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084789 Homologous recombination deficiency positive advanced ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004278-76 Sponsor Protocol Number: GINECO-OV129b Start Date*: 2021-11-22
    Sponsor Name:ARCAGY-GINECO
    Full Title: A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With...
    Medical condition: Advanced ovarian, tubal or peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004060-11 Sponsor Protocol Number: 0403 Start Date*: 2016-04-25
    Sponsor Name:ImmunoGen, Inc.
    Full Title: FORWARD1: A Randomized, Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator?s Choice of Chemotherapy in Adults with Folate Recept...
    Medical condition: Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Primary Fallopian Tube Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) PL (Completed) BG (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001219-22 Sponsor Protocol Number: SGNTV-002 Start Date*: 2019-10-25
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
    Medical condition: Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000662-18 Sponsor Protocol Number: CORT125134-556 Start Date*: 2023-02-27
    Sponsor Name:CORCEPT THERAPEUTICS
    Full Title: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian...
    Medical condition: Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002326-24 Sponsor Protocol Number: ALKS4230-007 Start Date*: 2023-02-13
    Sponsor Name:Mural Oncology, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial O...
    Medical condition: Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Completed) IT (Trial now transitioned) NO (Trial now transitioned) AT (Ongoing) LT (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005471-24 Sponsor Protocol Number: GINECO-OV236b Start Date*: 2016-04-19
    Sponsor Name:ARCAGY-GINECO
    Full Title: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chem...
    Medical condition: Patients with late relapse of epithelial ovarien cancer, fallopian tube or peritoneal cancer treated with chemotherapy , bevacizumab and a anti PD-L1
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing) AT (Completed) DE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001790-23 Sponsor Protocol Number: GCT1047-01 Start Date*: 2021-09-27
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors
    Medical condition: Malignant Solid Tumors, per protocol GCT1047-01
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005448-18 Sponsor Protocol Number: MORAb-009-003 Start Date*: 2009-06-04
    Sponsor Name:Morphotek, Inc.
    Full Title: An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
    Medical condition: Advanced pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000734-30 Sponsor Protocol Number: D0816C00012 Start Date*: 2015-07-10
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germli...
    Medical condition: BRCA or HRR+ Mutated Ovarian Cancer Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000816-14 Sponsor Protocol Number: CO-338-043 Start Date*: 2016-11-24
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Medical condition: Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038977 Retroperitoneal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002782-20 Sponsor Protocol Number: H3E-MC-JMHH Start Date*: 2005-04-15
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer
    Medical condition: platinum sensitive recurrent ovarian or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004628-34 Sponsor Protocol Number: HECTOR_PhaseIII_2006 Start Date*: 2007-02-05
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie...
    Medical condition: Patientinnen mit epithelialem Ovarialkarzinom, Peritoneal- oder Tubenkarzinom und Rezidiv / Progress ≥ 6 Monate nach Ende einer platinhaltigen Primär- oder Sekundärtherapie und Taxan in einer der V...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 04:19:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA